TGA approves Mounjaro for weight loss amid global shortage
The dual GLP-1 and glucose-dependent insulinotropic polypeptide agonist was originally approved for controlling type 2 diabetes.
The TGA has approved tirzepatide, marketed as Mounjaro, for the treatment of obesity and overweight, even as the drug faces a global shortage.
The dual GLP-1 and glucose-dependent insulinotropic polypeptide agonist was previously approved for controlling type 2 diabetes, as an adjunct to diet and exercise.
But after almost a year under evaluation, it is now approved for weight loss for adults with an initial BMI of 30kg/m2 or more.
It is also approved for patients with overweight (BMI 27kg/m2 or more) with at least one weight-related comorbid condition.
